The Respiratory Syncytial Virus (RSV) Therapeutics Market Size was valued at USD 1.37 billion in 2023 and is projected to reach USD 4.64 billion by 2032, expanding at a Compound Annual Growth Rate (CAGR) of 14.5% from 2024 to 2032. The sharp rise in global RSV infections—particularly among infants, immunocompromised individuals, and the elderly—has created an urgent demand for...